Acadia Healthcare Company, Inc.

DB:7RA Stock Report

Market Cap: €3.6b

Acadia Healthcare Company Valuation

Is 7RA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 7RA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 7RA (€38.2) is trading above our estimate of fair value (€6.35)

Significantly Below Fair Value: 7RA is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 7RA?

Key metric: As 7RA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 7RA. This is calculated by dividing 7RA's market cap by their current earnings.
What is 7RA's PE Ratio?
PE Ratio13.7x
EarningsUS$280.73m
Market CapUS$3.83b

Price to Earnings Ratio vs Peers

How does 7RA's PE Ratio compare to its peers?

The above table shows the PE ratio for 7RA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.9x
RHK RHÖN-KLINIKUM
18.9x7.5%€850.1m
M12 M1 Kliniken
17.5x17.5%€293.2m
LIK LIMES Schlosskliniken
23.2xn/a€99.1m
SYAB SYNLAB
28x-11.4%€2.5b
7RA Acadia Healthcare Company
13.7x11.6%€3.8b

Price-To-Earnings vs Peers: 7RA is good value based on its Price-To-Earnings Ratio (13.7x) compared to the peer average (21.9x).

Price to Earnings Ratio vs Industry

How does 7RA's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
7RA 13.7xIndustry Avg. 18.5xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 7RA is good value based on its Price-To-Earnings Ratio (13.7x) compared to the European Healthcare industry average (18.8x).

Price to Earnings Ratio vs Fair Ratio

What is 7RA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

7RA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.7x
Fair PE Ratio24.5x

Price-To-Earnings vs Fair Ratio: 7RA is good value based on its Price-To-Earnings Ratio (13.7x) compared to the estimated Fair Price-To-Earnings Ratio (24.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 7RA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€38.20
€57.78
+51.3%
18.7%€76.82€41.29n/a12
Nov ’25€39.00
€63.67
+63.3%
20.8%€86.74€41.53n/a12
Oct ’25€56.50
€79.48
+40.7%
10.1%€94.04€67.17n/a12
Sep ’25€72.50
€81.86
+12.9%
9.3%€96.21€68.72n/a12
Aug ’25€59.50
€81.86
+37.6%
11.4%€97.30€64.87n/a12
Jul ’25€62.50
€82.62
+32.2%
11.3%€97.84€65.23n/a12
Jun ’25€62.00
€81.68
+31.7%
11.3%€96.73€64.48n/a12
May ’25€69.50
€88.45
+27.3%
9.8%€96.89€64.60n/a13
Apr ’25€72.00
€87.72
+21.8%
10.1%€96.36€64.24n/a12
Mar ’25€77.00
€87.47
+13.6%
11.5%€97.15€64.76n/a11
Feb ’25€76.00
€81.84
+7.7%
11.1%€95.97€62.15n/a11
Jan ’25€70.50
€80.97
+14.8%
11.5%€96.01€62.18n/a11
Dec ’24€66.50
€82.59
+24.2%
11.5%€97.93€63.42n/a11
Nov ’24€69.00
€84.86
+23.0%
11.7%€98.90€64.05€39.0011
Oct ’24€66.50
€84.74
+27.4%
11.3%€98.27€63.64€56.5011
Sep ’24€71.00
€82.95
+16.8%
11.0%€95.97€62.15€72.5012
Aug ’24€71.50
€82.38
+15.2%
11.0%€95.49€61.84€59.5012
Jul ’24€73.00
€81.45
+11.6%
12.0%€95.29€57.17€62.5012
Jun ’24€66.00
€81.45
+23.4%
12.0%€95.29€57.17€62.0012
May ’24€66.00
€81.45
+23.4%
12.0%€95.29€57.17€69.5012
Apr ’24€65.00
€86.40
+32.9%
8.8%€98.34€70.25€72.0012
Mar ’24€68.50
€87.62
+27.9%
6.7%€98.48€76.91€77.0012
Feb ’24€77.00
€89.96
+16.8%
6.7%€99.78€77.92€76.0012
Jan ’24€77.00
€89.55
+16.3%
7.0%€99.68€77.84€70.5012
Dec ’23€85.50
€89.70
+4.9%
8.0%€101.37€77.23€66.5012
Nov ’23€82.00
€92.99
+13.4%
8.9%€106.30€80.99€69.0013

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-0.9%

1Y

-35.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%

OrbusNeich Medical Group Holdings

HK$3.1b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

Q8T

HK$0.40

7D

-21.2%

1Y

-46.9%